Fox Chase Cancer Center News

PHILADELPHIA (June 2, 2018) – In recent years the Food and Drug Administration has approved several new drugs for men with newly diagnosed metastatic prostate cancer. A new study compares the cost-effectiveness of intravenous docetaxel (DC) and daily pill abiraterone acetate plus prednisone (AAP) and analyzes progression free and overall survival for each.

PHILADELPHIA (June 1, 2018) – National Cancer Survivors Day is June 3rd. Fox Chase Cancer Center is celebrating the lives of cancer survivors across the country. According to the National Cancer Institute, the term “cancer survivor” refers to any person with a history of cancer, from the time of diagnosis through the remainder of their life.

PHILADELPHIA (May 30, 2018) – Scientists seeking a path to better patient outcomes in ovarian cancer have discovered that a scaffolding protein known to promote breast cancer and melanoma metastasis, but aid in suppressing hematologic cancers, is associated with aggressive ovarian tumor growth. 

PHILADELPHIA (May 25, 2018) – A growing body of research shows that cilia, minuscule protuberances on the surface of some cells, play a pivotal role in determining whether cancer cells grow, spread, and respond to therapy.

PHILADELPHIA (May 24, 2018) – As nearly 40,000 cancer researchers, physicians, and advocates gather in Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting, nearly 20 Fox Chase Cancer Center faculty and students will present their research on a range of topics. 

PHILADELPHIA (May 23, 2018) – Mariusz A. Wasik, MD, has been appointed Chair of the Department of Pathology at Fox Chase Cancer Center and Jeanes Hospital, joining the faculty on July 2.. He will also serve as Associate Director of the Cancer Center. 

PHILADELPHIA (May 19, 2018) – Androgen deprivation therapy (ADT) comes with the risk of side effects, and the effects increase as the therapy is given. Physicians at Fox Chase Cancer Center have determined that local cryosurgery is a viable option to delay or avoid ADT for many of these men.

PHILADELPHIA (May 19, 2018) – Researchers at Fox Chase Cancer Center are seeking to solve a diagnostic dilemma inherent in current treatment recommendations for bladder cancer. This trial marks the first time the true negative predictive value of a normal cystoscopic evaluation  is being identified, allowing researchers to establish how often bladder cancer hides under the mucosa and evades endoscopic diagnosis.